IVI RMA Global, recognised as the world's leading reproductive medicine platform, has confirmed that following the completion of its acquisition of ART Fertility Clinics ("ART Fertility") -- operating in the United Arab Emirates and preparing to launch in Saudi Arabia -- the Middle East has now been designated as the Company's newest Operating Region. It now joins other regions including North America, Italy, Northern Europe, and Iberia, Latam & Czechia. Under the direction of ART Fertility Clinics CEO Suresh Soni and Medical Director Dr. Human M. Fatemi, the establishment of this regional structure will enable IVI RMA to deliver fertility services to tens of thousands of patients across the Middle East.

Recent figures from the World Bank (2023) indicate increasingly low fertility rates across the Middle East, with the UAE recording 1.2 births per woman and Saudi Arabia experiencing a continued decline. These trends point to a significant demographic shift and slower population growth across the region.

"Across the Middle East, there is a growing awareness of the importance of addressing fertility challenges directly, and we are seeing more individuals and couples seeking advanced solutions every day," said Dr. Fatemi. "As part of IVI RMA, we will have the resources to build on our success in delivering these treatments, accelerate our scientific progress, and elevate the standard of fertility care across the region."

ART Fertility is widely regarded as the leading fertility provider in the Gulf Cooperation Council (GCC), operating throughout the Arabian Peninsula. With more than 300 staff, including leading clinicians, embryologists, and geneticists, supported by an experienced management team, the organisation has used proprietary research, specialised protocols, and personalised treatment pathways to consistently deliver pregnancy success rates reaching 71% across various age categories.

"The entire ART Fertility team is excited about this combination of two leaders in global fertility meeting the fertility challenge in the Middle East," said Mr. Soni. "Together we will bring even greater value to our patients and communities and will enhance the groundbreaking work our researchers are conducting to drive innovation that improves outcomes for people building families in the Middle East and around the world."

ART Fertility is globally recognised not only for its clinical excellence but also for its scientific output, supported by substantial investment in research and development. To date, the clinic has produced over 268 peer-reviewed medical papers, initiated 35 ongoing research projects, and hosted 11 scientific conferences. Its extensive scientific contributions strengthen patient care, serve as an international benchmark for quality, and align with IVI RMA's focus on clinical innovation and medical advancement.

"We are always looking for quality organizations that meet our high standards and whose own success can strengthen our work," said Javier Sánchez Prieto, CEO of IVI RMA Global. "We believe strongly that the Middle East will see continued demand for excellence in fertility care and that the acquisition of ART Fertility has IVI RMA well positioned to lead this trend and continue to play a major role in the advancement of fertility science and practice in the region."

source:newsreleases.co.uk